Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,100Open textbooks2Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology107Genetics and Genomics95Neuroscience110Cardiovascular Medicine105Immunology90Pharmacology99Molecular Biology100Infectious Diseases102Rare and Inherited Diseases106Clinical Research98Anatomy and Physiology542Drugs and Chemicals546
Plans & pricingCompare EvidenceHelix workspace plans
Library›EvidenceLib›Genetics and Genomics›RNA Interference
Explore more with EvidenceHelix Workspace

Compare studies, analyze evidence and create research reports with premium tools.

Explore Researcher plans

Research reading room

RNA Interference

Genetics and Genomics · NLM MeSH · updated 2026-10-29 · version 1

Citations verified against PubMedNot yet clinician-reviewed10 referencesApproximately 5 min read

A gene silencing phenomenon whereby specific dsRNAs (RNA, double-stranded) trigger the degradation of homologous mRNA (RNA, messenger).

Table of Contents

1. Definition2. Research landscape3. Reading the evidence4. Open-access studies5. Key reviews6. References7. About this article

Definition and research guide

This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.

Content available: 4 complete abstracts (850 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.

Definition

A gene silencing phenomenon whereby specific dsRNAs (RNA, double-stranded) trigger the degradation of homologous mRNA (RNA, messenger). The specific dsRNAs are processed into small interfering rna (siRNA) which serves as a guide for cleavage of the homologous mRNA in the rna-induced silencing complex. dna methylation may also be triggered during this process.

Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.

Also known as: Interference, RNA; RNAi; Posttranscriptional Gene Silencing; Gene Silencing, Posttranscriptional; Gene Silencings, Posttranscriptional; RNA Silencing; Post-Transcriptional Gene Silencing; Post Transcriptional Gene Silencing.

Where it fits in the MeSH classification

Broader topics
Gene Silencing
See also
RNA, Small Interfering; RNA-Induced Silencing Complex; RNAi Therapeutics

Related concepts

  • Double-Stranded
  • Messenger
  • Small Interfering Rna
  • Rna-Induced Silencing Complex
  • Dna Methylation

Research landscape

PubMed indexes 58,367 records tagged with the MeSH heading “RNA Interference” (counts retrieved 2026-10-29). 6,518 of them (11.2%) were published from 2020 onward, and the busiest period so far is 2010-2019 with 38,090 records.

Reviews account for 4,081 records (7.0%) and meta-analyses for 40. Randomized controlled trials number 31 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.

PubMed records by publication periodthrough 1999: 0 records; 2000-2009: 14,423 records; 2010-2019: 38,090 records; 2020 onward: 6,518 records0through 199914,4232000-200938,0902010-20196,5182020 onward
Records in PubMed indexed with this heading, by publication period. Real counts from NCBI E-utilities; the final period covers only part of the current year. Volume reflects how much has been published, not how strong the evidence is.
Show the data
PeriodRecords
through 19990
2000-200914,423
2010-201938,090
2020 onward6,518
Share of records by publication typeReviews: 7.0 percent; Meta-analyses: 0.1 percent; Randomized controlled trials: 0.1 percentReviews7.0% (4,081)Meta-analyses0.1% (40)Randomized controlled trials0.1% (31)
Share of all PubMed records on this heading that carry each publication type. Types overlap with other records, so the shares do not sum to 100%.
Publication-type chart data
Publication types among 58,367 PubMed records
TypeRecordsShare
Reviews4,0817.0%
Meta-analyses400.1%
Randomized controlled trials310.1%

Method: PubMed query "RNA Interference"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.

Reading the evidence in genetics and genomics

Genetic findings vary widely in strength. A variant linked to a condition in one study may not replicate in other ancestries, and most common variants have small effects that are meaningful only in aggregate. Studies of rare, high-impact variants can support strong causal claims about a gene, while association studies describe statistical links that need functional and independent replication. Check the sample size, the ancestry of participants, whether results were replicated, and whether a laboratory or clinical outcome was actually measured.

Evidence from open-access studies

These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.

Study comparison — selected abstracts, not a systematic review
Study / authorsYearSource label / designEurope PMC citationsLicence / source
Post-Transcriptional Regulation of Immune Responses and Inflammatory Diseases by RNA-Binding ZFP36 Family Proteins
Makita S, Takatori H, Nakajima H
2021Review article
Design not recorded in structured metadata
132cc by
PMID 34276705 · DOI · PMC8282349
The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p
Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, et al.
2021Research article
Design not recorded in structured metadata
130cc by
PMID 34911533 · DOI · PMC8672580
Dicer dependent tRNA derived small RNAs promote nascent RNA silencing
Di Fazio A, Schlackow M, Pong SK, Alagia A, Gullerova M
2022Research article
Design not recorded in structured metadata
104cc by
PMID 35048990 · DOI · PMC8860591
Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in pathogenic Mucor fungi
Son YE, Pérez-Arques C, Heitman J
2026Research article
Design not recorded in structured metadata
4cc by
PMID 41628159 · DOI · PMC12863538

Post-Transcriptional Regulation of Immune Responses and Inflammatory Diseases by RNA-Binding ZFP36 Family Proteins [1]

Review article Makita S, Takatori H, Nakajima H · · 2021 · cited 132 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Post-transcriptional regulation is involved in the regulation of many inflammatory genes.
Closing excerpt
This review summarizes the current understanding of the post-transcriptional regulation of immunological responses and inflammatory diseases by RNA-binding ZFP36 family proteins.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (186 words)

Post-transcriptional regulation is involved in the regulation of many inflammatory genes. Zinc finger protein 36 (ZFP36) family proteins are RNA-binding proteins involved in messenger RNA (mRNA) metabolism pathways. The ZFP36 family is composed of ZFP36 (also known as tristetraprolin, TTP), ZFP36L1, ZFP36L2, and ZFP36L3 (only in rodents). The ZFP36 family proteins contain two tandemly repeated CCCH-type zinc-finger motifs, bind to adenine uridine-rich elements in the 3'-untranslated regions (3' UTR) of specific mRNA, and lead to target mRNA decay. Although the ZFP36 family members are structurally similar, they are known to play distinct functions and regulate different target mRNAs, probably due to their cell-type-specific expression patterns. For instance, ZFP36 has been well-known to function as an anti-inflammatory modulator in murine models of systemic inflammatory diseases by down-regulating the production of various pro-inflammatory cytokines, including TNF-α. Meanwhile, ZFP36L1 is required for the maintenance of the marginal-zone B cell compartment. Recently, we found that ZFP36L2 reduces the expression of Ikzf2 (encoding HELIOS) and suppresses regulatory T cell function. This review summarizes the current understanding of the post-transcriptional regulation of immunological responses and inflammatory diseases by RNA-binding ZFP36 family proteins.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34276705 · DOI · PMC8282349

The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p [2]

Research article Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, et al. · · 2021 · cited 130 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
BackgroundDysregulation of circular RNAs (circRNAs) plays an important role in the development of gastric cancer; thus, revealing the biological and molecular mechanisms of abnormally expressed circRNAs is critical for identifying novel therapeutic targets in gastric cancer.
Closing excerpt
ConclusionsOverall, our findings demonstrate how circDLG1 promotes gastric cancer cell proliferation, migration, invasion and immune evasion and provide a new perspective on the role of circRNAs during gastric cancer progression.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (239 words)

BackgroundDysregulation of circular RNAs (circRNAs) plays an important role in the development of gastric cancer; thus, revealing the biological and molecular mechanisms of abnormally expressed circRNAs is critical for identifying novel therapeutic targets in gastric cancer.MethodsA circRNA microarray was performed to identify differentially expressed circRNAs between primary and distant metastatic tissues and between gastric cancer tissues sensitive or resistant to anti-programmed cell death 1 (PD-1) therapy. The expression of circRNA discs large homolog 1 (DLG1) was determined in a larger cohort of primary and distant metastatic gastric cancer tissues. The role of circDLG1 in gastric cancer progression was evaluated both in vivo and in vitro, and the effect of circDLG1 on the antitumor activity of anti-PD-1 was evaluated in vivo. The interaction between circDLG1 and miR-141-3p was assessed by RNA immunoprecipitation and luciferase assays.ResultscircDLG1 was significantly upregulated in distant metastatic lesions and gastric cancer tissues resistant to anti-PD-1 therapy and was associated with an aggressive tumor phenotype and adverse prognosis in gastric cancer patients treated with anti-PD-1 therapy. Ectopic circDLG1 expression promoted the proliferation, migration, invasion, and immune evasion of gastric cancer cells. Mechanistically, circDLG1 interacted with miR-141-3p and acted as a miRNA sponge to increase the expression of CXCL12, which promoted gastric cancer progression and resistance to anti-PD-1-based therapy.ConclusionsOverall, our findings demonstrate how circDLG1 promotes gastric cancer cell proliferation, migration, invasion and immune evasion and provide a new perspective on the role of circRNAs during gastric cancer progression.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 34911533 · DOI · PMC8672580

Dicer dependent tRNA derived small RNAs promote nascent RNA silencing [3]

Research article Di Fazio A, Schlackow M, Pong SK, Alagia A, Gullerova M · · 2022 · cited 104 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
In mammalian cells, small non-coding RNAs (sncRNAs) negatively regulate gene expression in a pathway known as RNA interference (RNAi).
Closing excerpt
Finally, we show that NRS is evolutionarily conserved and has the potential to be explored as a novel synthetic sRNA based therapeutic.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (200 words)

In mammalian cells, small non-coding RNAs (sncRNAs) negatively regulate gene expression in a pathway known as RNA interference (RNAi). RNAi can be categorized into post-transcriptional gene silencing (PTGS), which involves the cleavage of target messenger RNA (mRNA) or inhibition of translation in the cytoplasm, and transcriptional gene silencing (TGS), which is mediated by the establishment of repressive epigenetic marks at target loci. Transfer RNAs (tRNAs), which are essential for translation, can be processed into small ncRNAs, termed tRNA-derived small RNAs (tsRNAs). The biogenesis of tsRNAs and their role in gene expression regulation has not yet been fully understood. Here, we show that Dicer dependent tsRNAs promote gene silencing through a mechanism distinct from PTGS and TGS. tsRNAs can lead to downregulation of target genes by targeting introns via nascent RNA silencing (NRS) in nuclei. Furthermore, we show that Ago2 slicer activity is required for this mechanism. Synthetic tsRNAs can significantly reduce expression of a target gene at both RNA and protein levels. Target genes regulated by NRS are associated with various diseases, which further underpins its biological significance. Finally, we show that NRS is evolutionarily conserved and has the potential to be explored as a novel synthetic sRNA based therapeutic.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 35048990 · DOI · PMC8860591

Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in pathogenic Mucor fungi [4]

Research article Son YE, Pérez-Arques C, Heitman J · · 2026 · cited 4 times (Europe PMC)

Abstract reading summary — source excerpts
Opening excerpt
Antimicrobial resistance (AMR) is a global health threat emerging through microbe adaptation, driven by genetic variation, genome plasticity or epigenetic processes.
Closing excerpt
These findings reveal that antifungal resistance arising through distinct, transient epimutation pathways involving RNAi or heterochromatin, highlighting adaptive AMR strategies employed by ubiquitous eukaryotic microbes.
Interpretation limits
Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (225 words)

Antimicrobial resistance (AMR) is a global health threat emerging through microbe adaptation, driven by genetic variation, genome plasticity or epigenetic processes. In this study, we investigated how the Mucor circinelloides species complex adapts to the antifungal natural product FK506, which binds to FKBP12 and inhibits calcineurin-dependent hyphal growth. In Mucor bainieri, most FK506-resistant isolates (90%) were found to be unstable and transient, readily reverting to being drug sensitive when passaged without drug, and with no associated DNA mutations. In half of the isolates (50%), FK506-resistance was conferred by RNAi-dependent epimutation in which small interfering RNAs (siRNAs) silenced the fkbA encoding FKBP12 post-transcriptionally. In contrast, most of the remaining FK506-resistant isolates (40%) were found to have undergone heterochromatin-mediated silencing via H3K9 dimethylation, transcriptionally repressing fkbA and neighboring genes. In these heterochromatic epimutants, only minimal enrichment of siRNA to the fkbA locus was observed, but in three of the four examples, siRNA was significantly enriched at a locus distant from fkbA. A similar mechanism operates in Mucor atramentarius, where FK506 resistance was mediated by ectopic heterochromatin silencing of fkbA and associated genes with siRNA spreading across the region. Heterochromatin-mediated fkbA epimutants exhibited stability during in vivo infection, suggesting epimutation could impact pathogenesis. These findings reveal that antifungal resistance arising through distinct, transient epimutation pathways involving RNAi or heterochromatin, highlighting adaptive AMR strategies employed by ubiquitous eukaryotic microbes.

Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41628159 · DOI · PMC12863538

Key reviews and meta-analyses

The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.

  • Research article Endogenous microRNA sponges: evidence and controversy [5]
    Thomson DW, Thomson DW, Dinger ME · Nat Rev Genet · 2016 · cited 1,743 times (Europe PMC)
  • Research article The current state and future directions of RNAi-based therapeutics [6]
    Setten RL, Rossi JJ, Han SP · Nat Rev Drug Discov · 2019 · cited 1,132 times (Europe PMC)
  • Research article MiRNA Biogenesis and Regulation of Diseases: An Overview [7]
    Vishnoi A, Rani S · Methods Mol Biol · 2017 · cited 521 times (Europe PMC)
  • Research article Mechanisms, Applications, and Challenges of Insect RNA Interference [8]
    Zhu KY, Palli SR · Annu Rev Entomol · 2020 · cited 463 times (Europe PMC)
  • Research article RNAi-based therapeutics and tumor targeted delivery in cancer [9]
    Kara G, Calin GA, Ozpolat B, Ozpolat B · Adv Drug Deliv Rev · 2022 · cited 299 times (Europe PMC)
  • Research article The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation [10]
    Stavast CJ, Erkeland SJ · Cells · 2019 · cited 282 times (Europe PMC)

References

  1. Makita S, Takatori H, Nakajima H. Post-Transcriptional Regulation of Immune Responses and Inflammatory Diseases by RNA-Binding ZFP36 Family Proteins. . 2021. PMID 34276705 · DOI · PMC8282349
  2. Chen DL, Sheng H, Zhang DS, Jin Y, Zhao BT, Chen N, et al.. The circular RNA circDLG1 promotes gastric cancer progression and anti-PD-1 resistance through the regulation of CXCL12 by sponging miR-141-3p. . 2021. PMID 34911533 · DOI · PMC8672580
  3. Di Fazio A, Schlackow M, Pong SK, Alagia A, Gullerova M. Dicer dependent tRNA derived small RNAs promote nascent RNA silencing. . 2022. PMID 35048990 · DOI · PMC8860591
  4. Son YE, Pérez-Arques C, Heitman J. Epimutations driven by RNAi or heterochromatin evoke transient antimicrobial drug resistance in pathogenic Mucor fungi. . 2026. PMID 41628159 · DOI · PMC12863538
  5. Thomson DW, Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet. 2016. PMID 27040487 · DOI
  6. Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019. PMID 30846871 · DOI
  7. Vishnoi A, Rani S. MiRNA Biogenesis and Regulation of Diseases: An Overview. Methods Mol Biol. 2017. PMID 27826912 · DOI
  8. Zhu KY, Palli SR. Mechanisms, Applications, and Challenges of Insect RNA Interference. Annu Rev Entomol. 2020. PMID 31610134 · DOI · PMC9939233
  9. Kara G, Calin GA, Ozpolat B, Ozpolat B. RNAi-based therapeutics and tumor targeted delivery in cancer. Adv Drug Deliv Rev. 2022. PMID 35063535 · DOI
  10. Stavast CJ, Erkeland SJ. The Non-Canonical Aspects of MicroRNAs: Many Roads to Gene Regulation. Cells. 2019. PMID 31752361 · DOI · PMC6912820

About this article

Sources
NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
Verification
Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
Review state
automated source verified; no human expert review has been recorded yet.
Version
1, last updated 2026-10-29.

See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.

Evidence strength

EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.

Included with the Researcher plan

Reading every article stays free. This computed view is part of the paid plans.

See plans Sign in

Your notes

Notes and highlights stay in this browser only; they are not sent to EvidenceHelix.

Related research topics

  • Genomic ImprintingGenetics and Genomics
  • CRISPR-Cas SystemsGenetics and Genomics
  • X Chromosome InactivationGenetics and Genomics
  • Gene RearrangementGenetics and Genomics
  • AnticodonGenetics and Genomics
  • ExonsGenetics and Genomics

All 95 articles in Genetics and Genomics →

At a glance

58,367
PubMed records on this heading
11%
published since 2020
4,081
review articles
31
randomized trials
10
verified references below

Counts come from PubMed on 2026-10-29; they show how much has been written, not how strong the evidence is.

Related topics See all →

  • Genomic ImprintingGenetics and Genomics
  • CRISPR-Cas SystemsGenetics and Genomics
  • X Chromosome InactivationGenetics and Genomics
  • Gene RearrangementGenetics and Genomics
  • AnticodonGenetics and Genomics

My notes & annotations (0)

Nothing yet. Select text and press Highlight, or write a note in the Notes tab. Stored in this browser only.

Sources

  • NLM MeSH record ↗
  • PubMed search used ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Legal · Support